A. Bani, M. Miniati - Vol. 10, June 2004, Issue 2
Testo Immagini Bibliografia Summary Indice
Sindrome da Sospensione da SSRI: un contributo
clinico
Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome: a
case report
1 Barbui C, Campomori A, D’Avanzo B, Negri E, Garattini S. Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol 1999;34:152-6.
2 Tyrer P. Clinical effects of abrupt withdrawal from TCA and IMAO after long term treatment. J Affect Disord 1984;6:1-7.
3 Medawar C. The antidepressant web. Marketing depression and making medicine work. Int J Risk Saf Med 1997;10:75-126.
4 Lader M. Benzodiazepine Withdrawal states. In: Trimble MR, ed. Benzodiazepines Divided. New York NY: John Wiley & Sons 1983:17-31.
5 Ellison JM. Dr. Ellison replies (letter). J Clin Psychiatry 1996;57:310.
6 Haddad P. Newer antidepressants and discontinuation syndrome. J Clin Psychiatry 1997;58(Suppl 7):17-22.
7 Bani A, Cassano GB. La sospensione del trattamento con sostanze psicoattive. In: Psichiatria Medica, Utet 1990.
8 Dilsaver SC, Feinberg M, Greden JF. Antidepressant withdrawal symptoms treated with anticholinergic agents. Am J Psychiatry 1983;140:249-51.
9 Ellison JM. SSRI Withdrawal buzz (letter). Am J Psychiatry 1993;55:544-5.
10 Farah A, Lauer T. Possible venlafaxine withdrawal reaction (letter). Am J Psychiatry 1996;153:576.
11 Mallya G, White K, Gunderson C. Is there a serotoninergic withdrawal syndrome? Biol Psychiatry 1993;33:851-2.
12 Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine (letter). Am J Psychiatry 1991;148:1263.
13 Bhaumik S, Wildgust HJ. Letter to the Editor. Hum Psychopharmacol 1996;11:337-8.
14 Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-62.
15 Rosenbaum J, Fava M, Hoog SL, Ascroft R, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44:77-87.
16 Tarolla E, D’Andrea A, Cantelmi T. Paroxetina: tossicità, tollerabilità e usi atipici nella pratica clinica. Ital J Psychopathol 2003;9:163-71.
17 Mori S, Perez J, Tardito D. I citocromi p450. Dalla biologia alla terapia antidepressiva. Milano: Masson 1999.
18 D’Arcy PF. Dystonia and Withdrawal symptoms with paroxetine (letter). Int Pharm J 1993;7:140.
19 Pacheco L, Malo P, Aragues E. More cases of paroxetine withdrawal syndrome (letter). Br J Psychiatry 1996;169:384.
20 Pyke RE. Paroxetine Witdrawal syndrome (letter). Am J Psychiatry 1995;152:149-50.
21 Iapichino S, Colzi A, Massimo V. Inibitori selettivi del reuptake della serotonina – ISRS – Sindrome da sospensione: fattori patogenetici e differenziazione tra i diversi SSRI. Ital J Psychopathol 2000;6:180-6.
22 Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation (letter). Am J Psychiatry 1994;151:289.
23 Dilsaver SC, Greden JF, Snider RM. Antidepressant withdrawal syndromes phenomenology and phisiopathology. Int Clin Psychopharmacol 1987;2:1-19.